Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Target Price of $5.46 According to Brokerages

Cellectis S.A. (NASDAQ:CLLS) has earned an average recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $5.46.

A number of brokerages have commented on CLLS. Wells Fargo & Company decreased their price objective on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday, September 15th. Weiss Ratings cut shares of Cellectis from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Citizens Jmp reaffirmed a “market perform” rating on shares of Cellectis in a report on Tuesday, September 15th. Robert W. Baird decreased their price objective on Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 15th. Finally, Barclays cut Cellectis from an “overweight” rating to an “underweight” rating and lowered their target price for the company from $9.00 to $1.30 in a research note on Wednesday, September 16th.

Hedge Funds Weigh In On Cellectis

An institutional investor recently bought a new position in Cellectis stock. Lido Advisors LLC purchased a new position in Cellectis S.A. (NASDAQ:CLLS) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Trading Up 2.1%

Shares of CLLS stock opened at $1.43 on Wednesday. The company has a market capitalization of $143.48 million, a P/E ratio of -2.20 and a beta of 3.01. Cellectis has a 12-month low of $1.25 and a 12-month high of $5.48. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61. The firm has a 50-day moving average price of $2.61 and a 200 day moving average price of $3.12.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.The business had revenue of $6.90 million for the quarter, compared to analyst estimates of $11.05 million.

Cellectis Company Profile

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.